RGEN – Repligen Corporation
RGEN — Price & Forward EBITDA
Forward EBITDA (M)
Float Short %
8.15
Margin Of Safety %
-11
Put/Call OI Ratio
1.35
EPS Next Q Diff
-0.02
EPS Last/This Y
1.09
EPS This/Next Y
0.54
Price
115.28
Target Price
185.88
Analyst Recom
1.45
Performance Q
-31.96
Upside
-73.9%
Beta
1.17
Ticker: RGEN
of 1
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2026-03-09 | RGEN | 127.91 | 0.90 | 0.05 | 9059 |
| 2026-03-10 | RGEN | 121.82 | 0.76 | 0.39 | 8472 |
| 2026-03-11 | RGEN | 120.03 | 0.76 | 0.14 | 8499 |
| 2026-03-12 | RGEN | 113.74 | 0.76 | 0.28 | 8504 |
| 2026-03-13 | RGEN | 113.76 | 0.76 | 0.28 | 8504 |
| 2026-03-17 | RGEN | 119.35 | 0.76 | 13.22 | 8536 |
| 2026-03-18 | RGEN | 117.59 | 0.87 | 3.00 | 9205 |
| 2026-03-19 | RGEN | 117.6 | 0.87 | 0.47 | 9210 |
| 2026-03-20 | RGEN | 113.86 | 0.85 | 0.14 | 9085 |
| 2026-03-23 | RGEN | 116.34 | 1.52 | 0.06 | 5985 |
| 2026-03-24 | RGEN | 116.34 | 1.52 | 0.08 | 5991 |
| 2026-03-25 | RGEN | 114.2 | 1.52 | 105.94 | 5993 |
| 2026-03-26 | RGEN | 114.42 | 1.72 | 0.65 | 6504 |
| 2026-03-27 | RGEN | 110.17 | 1.72 | 8.35 | 6519 |
| 2026-03-30 | RGEN | 111.45 | 1.40 | 0.20 | 6937 |
| 2026-03-31 | RGEN | 117.91 | 1.39 | 0.00 | 6946 |
| 2026-04-01 | RGEN | 118.38 | 1.39 | 1.38 | 6948 |
| 2026-04-02 | RGEN | 117.79 | 1.39 | 0.01 | 6959 |
| 2026-04-06 | RGEN | 117.04 | 1.35 | 0.97 | 7047 |
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2026-03-09 | RGEN | 127.92 | -0.6 | 0.9 | 1.96 |
| 2026-03-10 | RGEN | 121.78 | -0.6 | -8.2 | 1.96 |
| 2026-03-11 | RGEN | 119.18 | -0.6 | -6.2 | 1.96 |
| 2026-03-12 | RGEN | 113.73 | -0.6 | -8.1 | 1.96 |
| 2026-03-13 | RGEN | 114.18 | -0.7 | -4.1 | 1.96 |
| 2026-03-17 | RGEN | 119.30 | -0.7 | -1.5 | 1.96 |
| 2026-03-18 | RGEN | 117.57 | -0.7 | -5.5 | 1.96 |
| 2026-03-19 | RGEN | 117.60 | -0.7 | -13.2 | 1.96 |
| 2026-03-20 | RGEN | 113.88 | -0.7 | -15.6 | 1.96 |
| 2026-03-23 | RGEN | 116.32 | -0.7 | -11.7 | 1.96 |
| 2026-03-24 | RGEN | 116.32 | -0.7 | -13.3 | 1.96 |
| 2026-03-25 | RGEN | 114.27 | -0.7 | -14.6 | 1.96 |
| 2026-03-26 | RGEN | 114.42 | -0.7 | -13.2 | 1.96 |
| 2026-03-27 | RGEN | 110.16 | -0.7 | -16.0 | 1.96 |
| 2026-03-30 | RGEN | 111.50 | -0.7 | -12.4 | 1.96 |
| 2026-03-31 | RGEN | 117.87 | -0.9 | -9.2 | 1.96 |
| 2026-04-01 | RGEN | 118.34 | -0.9 | -13.0 | 1.96 |
| 2026-04-02 | RGEN | 117.73 | -0.9 | -13.7 | 1.96 |
| 2026-04-06 | RGEN | 117.00 | -0.9 | -13.8 | 1.96 |
| 2026-04-07 | RGEN | 115.28 | -0.9 | -14.3 | 1.96 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2026-03-09 | RGEN | -2.66 | 3.17 | 7.60 |
| 2026-03-10 | RGEN | -2.66 | 3.17 | 7.60 |
| 2026-03-11 | RGEN | -2.66 | 3.17 | 7.52 |
| 2026-03-12 | RGEN | -1.75 | 3.17 | 7.52 |
| 2026-03-13 | RGEN | -1.75 | 3.17 | 7.52 |
| 2026-03-17 | RGEN | -1.75 | 3.19 | 7.52 |
| 2026-03-18 | RGEN | -1.75 | 3.19 | 7.52 |
| 2026-03-19 | RGEN | -1.75 | 3.19 | 7.52 |
| 2026-03-20 | RGEN | -1.75 | 3.19 | 7.52 |
| 2026-03-23 | RGEN | -1.75 | 3.19 | 7.52 |
| 2026-03-24 | RGEN | -1.75 | 3.19 | 7.52 |
| 2026-03-25 | RGEN | -1.75 | 3.19 | 8.15 |
| 2026-03-26 | RGEN | -1.75 | 3.19 | 8.15 |
| 2026-03-27 | RGEN | -1.75 | 3.19 | 8.15 |
| 2026-03-30 | RGEN | -1.75 | 3.19 | 8.15 |
| 2026-03-31 | RGEN | -1.75 | 3.19 | 8.15 |
| 2026-04-01 | RGEN | -1.75 | 3.19 | 8.15 |
| 2026-04-02 | RGEN | -1.75 | 3.19 | 8.15 |
| 2026-04-06 | RGEN | -1.75 | 3.19 | 8.15 |
| 2026-04-07 | RGEN | -1.75 | 3.19 | 8.15 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
0.49
Avg. EPS Est. Current Quarter
0.39
Avg. EPS Est. Next Quarter
0.47
Insider Transactions
-1.75
Institutional Transactions
3.19
Beta
1.17
Average Sales Estimate Current Quarter
192
Average Sales Estimate Next Quarter
203
Fair Value
102.09
Quality Score
70
Growth Score
77
Sentiment Score
47
Actual DrawDown %
64.8
Max Drawdown 5-Year %
-66.4
Target Price
185.88
P/E
133.38
Forward P/E
45.64
PEG
1.86
P/S
8.8
P/B
3.08
P/Free Cash Flow
70.83
EPS
0.86
Average EPS Est. Cur. Y
1.96
EPS Next Y. (Est.)
2.51
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
6.62
Relative Volume
0.78
Return on Equity vs Sector %
-25.1
Return on Equity vs Industry %
-7.2
EPS 1 7Days Diff
EPS 1 30Days Diff
EBIT Estimation
-14.3
◆
RGEN
Healthcare
$115.29
Swing / Pullback
Buy the dip on strong trends
WEAK
RSI
41
Range 1M
27.9%
Sup Dist
0%
Momentum Growth
Ride accelerating trends
WEAK
EPS Yr
16.4%
EPS NY
26.9%
52W%
14.1%
Long-Term Value
Quality companies, undervalued
WEAK
🔴 SELL
-3.1% upside
Upside
-3.1%
Quality
70
MoS
-11%
Repligen CorporationSector: Healthcare
Industry: Medical Instruments & Supplies
Employees: 2000
Repligen Corporation, a life sciences company, develops and commercializes bioprocessing technologies and systems in North America, Europe, the Asia Pacific, and internationally. The company's products include hollow fiber consumables, KRM chromatography system, resins for new modalities, PATsmart MAVERICK and PATsmart MAVEN for real-time monitoring and control of critical bioprocess parameters, PATsmart REBEL, an at-line cell culture media analyzer; and PATsmart ZipChip, a high-resolution sample separations device, PATsmart SoloVPE slope spectroscopy system, and SoloVPE PLUS System. It offers Protien A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products. The company also provides chromatography products, including OPUS pre-packed chromatography columns, which are used in the purification and quality control of biological drugs, as well as ELISA test kits. In addition, it offers filtration products, such as XCell ATF Cell Retention Systems that are filtration devices used in upstream perfusion and cell culture processing; TangenX flat sheet cassettes, which are used in downstream biologic drug concentration, buffer exchange, and formulation processes; KrosFlo tangential flow filtration and tangential flow depth filtration systems; and ProConnex TFDF flow paths. Further, it provides process analytics products, such as slope spectroscopy systems. The company offers its products under the OPUS, XCell, XCell ATF, TFDF, KrosFlo, SIUS, ProConnex, Spectra/Por, NGL-Impact, SoloVPE, FlowVPE, RPM, XO, Metenova MixOne, and AVIPure and FlowVPX brands. The company sells its products to life sciences, biopharmaceutical, and diagnostics companies; laboratory researchers; and contract manufacturing organizations. Repligen Corporation has a collaboration agreement with Navigo Proteins GmbH to develop multiple affinity ligands. The company was incorporated in 1981 and is headquartered in Waltham, Massachusetts.
RGEN
Latest News
—
Caricamento notizie per RGEN…
stock quote shares RGEN – Repligen Corporation Stock Price stock today
news today RGEN – Repligen Corporation stock forecast ,stock prediction 2023 2024 2025
marketwatch RGEN – Repligen Corporation yahoo finance google finance
stock history RGEN – Repligen Corporation invest stock market
stock prices RGEN premarket after hours
ticker RGEN fair value insiders trading